Improved Nucleic Acid Amplification Test for the Diagnosis of Onchocerciasis and Its Use for Detection of Circulating Cell-free DNA
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae462 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Sasisekhar Bennuru und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Onchocerciasis, Nucleic Acid Amplification Techniques, Onchocerca volvulus, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
Background
The coendemicity of onchocerciasis with other filariae warrants a better diagnostic tool for elimination efforts that are highly sensitive and specific for use in surveillance and xenomonitoring.
Methods
Based on next-generation sequencing data, quantitative polymerase chain reaction (qPCR) assays were designed for 15 highly repeated targets from Onchocerca volvulus (Ov) and 11 from Onchocerca ochengi. The 2 most promising repeats Ov15R and Ov16R from Ov and OoR1 and OoR5 from O. ochengi, were selected for further testing.
Results
The analytic sensitivity of Ov15R and Ov16R was similar, with limits of detection at 1 fg and specificity approaching 100%. Using DNA obtained previously from skin snips of participants infected with Ov, Ov16R identified 17 additional samples as positive for Ov infections when compared with the gold standard O-150. Although Ov16R failed to detect circulating cell-free DNA (ccfDNA) in the plasma of individuals infected with Ov, 1-mL urine samples were variably positive for ccfDNA. Interestingly, plasma levels of ccfDNA were shown to be easily measurable as early as 12 to 24 hours following treatment. To enable processing of larger volumes of urine for better sensitivity, a chitosan-based filter technique was developed that efficiently captured ccfDNA from 1 to 15 mL of urine. Interestingly, Ov15R, Ov16R, and O-150 map to the same region(s) of the Ov genome, prompting a redesign of the standard O-150 qPCR. This resulted in a new O-150 assay that performs on par with Ov15R/Ov16R.
Conclusions
Each of these assays dramatically improve detection of Ov DNA and can easily be configured to field-friendly isothermal formats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
- Department of Internal Medicine, Howard University Hospital, Washington DC.
- Genomics Unit, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
ORCID-Profile: Sasisekhar Bennuru
Förderung
- Division of Intramural Research
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Bennuru, S., Kodua, F., Dahlstrom, E., & Nutman, T. B. (2025). Improved Nucleic Acid Amplification Test for the Diagnosis of Onchocerciasis and Its Use for Detection of Circulating Cell-free DNA. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae462
Vancouver
Bennuru S, Kodua F, Dahlstrom E, Nutman TB. Improved Nucleic Acid Amplification Test for the Diagnosis of Onchocerciasis and Its Use for Detection of Circulating Cell-free DNA. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae462
BibTeX
@article{Bennuru2025,
author = {Bennuru, Sasisekhar and Kodua, Frimpong and Dahlstrom, Eric and Nutman, Thomas B},
title = {Improved Nucleic Acid Amplification Test for the Diagnosis of Onchocerciasis and Its Use for Detection of Circulating Cell-free DNA},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae462}
}
EUVIMED